Gedea Champions Both Women’s Health And The Fight Against Antibiotic Resistance
Exclusive Interview With CEO Annette Säfholm
Gedea Biotech is developing an antibiotic-free drug which could significantly improve the treatment of bacterial vaginosis. In Vivo spoke with CEO Annette Säfholm, a 2021 Rising Leader.
You may also be interested in...
New final guidance from NICE explains how best to avoid the risk of antibiotic resistance in patients with community- and hospital-acquired pneumonia.
Artios Pharma rides the wave of DDR enthusiasm following the recent signing of big pharma partnerships with a financing to bring its first-in-class cancer treatments into the clinic.
UK-based Immodulon Therapeutics is developing novel immunomodulators in the form of heat-killed bacteria, being trialed in combination with other cancer treatments such as checkpoint inhibitors. The biotech is initially looking at underserved areas, including pancreatic cancer.